Literature DB >> 8175130

Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.

A Tsubota1, K Chayama, K Ikeda, A Yasuji, I Koida, S Saitoh, M Hashimoto, S Iwasaki, M Kobayashi, K Hiromitsu.   

Abstract

To determine the patient-dependent and virus-related factors that may predict sustained response to interferon-alpha therapy, we prospectively evaluated 60 consecutive patients with chronic hepatitis C who received a standardized treatment schedule of interferon-alpha. Twenty-eight patients achieved a long-term sustained remission, 14 patients had temporary responses during treatment but relapsed after completing it and 14 patients did not respond. Four patients dropped out because of severe side effects and were excluded from evaluation of efficacy. Twenty-one variables were chosen as possible predictors of sustained response and were analyzed by means of multivariate analysis. Variables related to the hepatitis C virus included genotype and concentration in serum before treatment. The former was determined by means of the polymerase chain reaction with genotype-specific primers for genotypes PT, K1, K2a and K2b, which were deduced from nonstructural region 5 of the hepatitis C virus genome. The latter was measured with a competitive polymerase chain reaction technique. Three variables were statistically significant (p < 0.05) on univariate analysis: viral genotype, pretreatment level of viremia and Knodell's fibrosis score. In multivariate analysis viral genotype and Knodell's fibrosis score were correlated independently with a sustained response (p < 0.05 for both). Incidence of sustained response was 40% and 91% in patients with genotypes K1 and K2a, respectively. We conclude that with the treatment schedule used, viral genotype was the most useful predictor of a sustained response to treatment with interferon-alpha.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175130

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  75 in total

1.  High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group.

Authors:  Y Shiratori; R Nakata; N Shimizu; H Katada; S Hisamitsu; E Yasuda; M Matsumura; T Narita; K Kawada; M Omata
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month.

Authors:  A Magalini; M Puoti; V Putzolu; E Quiros-Roldan; M A Forleo; S Rossi; S Zaltron; A Spinetti; B Zanini; A Zonaro; R Solfrini; G Carosi
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

3.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 4.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

5.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

6.  Phylogenetic analysis of hepatitis C virus isolates from Tunisian patients.

Authors:  Ahlem Djebbi; Selma Mejri; Valerie Thiers; Henda Triki
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

7.  Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C.

Authors:  Kaori Mochizuki; Tatehiro Kagawa; Shinji Takashimizu; Kazuya Kawazoe; Sei-Ichiro Kojima; Naruhiko Nagata; Atsushi Nakano; Yasuhiro Nishizaki; Koichi Shiraishi; Masaru Itakura; Norihito Watanabe; Tetsuya Mine; Shohei Matsuzaki
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

8.  Hepatocyte regeneration in chronic hepatitis C and interferon treatment: analysis of immunohistological identification of proliferating cell nuclear antigen (PCNA).

Authors:  M Hamada; T Kihira; K Takase; T Nakano; Y Tameda; Y Kosaka
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

Review 9.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

10.  Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads.

Authors:  Hitomi Sezaki; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2008-10-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.